@ACTIV4a

Official account of the Accelerating COVID-19 Therapeutic Interventions and Vaccines Acute Inpatient Anti-Thrombotic Study (ACTIV-4a)

Joined December 2020
  • Tweets28
  • Following26
  • Followers232
>95% confidence in futility in non-critically #Covid_19 - @ACTIV4a still enrolling P2Y12 in critically ill patients - generating data at warp speed thanks to @NIHFunding @nih_nhlbi
Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦
@DrMarthaGulati15 Nov 2021
#AHA21 #LBCT P2y12 Inhibitors in Noncritically Ill Hospitalized Pts With #Covid_19 #ACTIV4A 🩸thrombosis/inflam in #COVID 🩸RCT of P2Yy12, non-critical pt: 562 pts 🩸Stopped for futility; 40% women; Ticag used in 63% 🩸 No benefit of P2Yy12 in non-critical pts @AHAMeetings
6
1
14
#AHA21 #LBCT P2y12 Inhibitors in Noncritically Ill Hospitalized Pts With #Covid_19 #ACTIV4A 🩸thrombosis/inflam in #COVID 🩸RCT of P2Yy12, non-critical pt: 562 pts 🩸Stopped for futility; 40% women; Ticag used in 63% 🩸 No benefit of P2Yy12 in non-critical pts @AHAMeetings
1
5
2
24
Superb @UofT_DoM Grand Rounds by @ecgoligher & @PatrickLawlerMD on the background, statistical approach & interpretation of the adaptive Bayesian design multiplatform @ATTACC_COVID / @ACTIV4a / @remap_cap anticoag in COVID trial. nejm.org/doi/full/10.1056/NE… nejm.org/doi/full/10.1056/NE…
4
13
ACTIV4a retweeted
NEJM
@NEJM4 Aug 2021
In noncritically ill patients with #COVID19, anticoagulation increased the probability of survival to hospital discharge without organ support. nej.md/3jrrxJx #IDTwitter
3
114
15
225
Great international collaboration @remap_cap @ATTACC_COVID @ACTIV4a
This Post is from an account that no longer exists. Learn more
6
21
The incredible efforts of so many have led to the publication of both #mpRCT papers reporting results of anticoagulation in #COVID19. @NEJM @ATTACC_COVID @remap_cap @ACTIV4a Most challenging/rewarding effort of my career nejm.org/doi/full/10.1056/NE… nejm.org/doi/full/10.1056/NE…

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 | NEJM

Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve ou...

nejm.org
3
18
63
Results of our therapeutic anticoagulation mpRCT with @ACTIV4a and @remap_cap is being live-streamed below. Results have now been published in the @NEJM Moderate state: bit.ly/3ioKptb Critically ill: bit.ly/3lxzn7c Editorial: bit.ly/3ltYnMj
Critical Care Reviews@CritCareReviews4 Aug 2021
pscp.tv/w/c9mKzXR3LTcwNTk0ND…

Critical Care Reviews @CritCareReviews

CritCareReviews was LIVE

pscp.tv
1
32
3
61
The final presentation timed with a public report. Come find out how the trial was done & what the role of therapeutic anticoagulation is in hospitalized patients with COVID-19. @ATTACC_COVID @remap_cap @ACTIV4a @UM_RadyFHS @UHN @CCCTG_ @canvector @ASH_hematology @JustinTrudeau
Critical Care Reviews@CritCareReviews3 Aug 2021
Big night tomorrow night! Free livestream from 20:30 UTC criticalcarereviews.com Supported by @MyIntensiveCare
17
1
42
Big night tomorrow night! Free livestream from 20:30 UTC criticalcarereviews.com Supported by @MyIntensiveCare
15
5
40
Replying to @RZarychanski @SCCM @ASH_hematology @UM_RadyFHS @CCCTG_ @ThrombosisCan @INVENT_VTE
Looking forward to discussing these results next week. This will impact COVID-19 practice worldwide 🌐 @ATTACC_COVID @remap_cap @ACTIV4a @charlot_summers @ecgoligher @PatrickLawlerMD
4
11
For patients with #COVID19 receiving organ support in the ICU, #antiplatelet therapy with aspirin or P2Y12 inhibitor (which were found to be equivalent), was ineffective at improving death and organ support free days when compared to no #antiplatelet therapy. 1/8
2
69
21
151
Final results of the mpRCT now on preprint server. In non-critically ill patients with COVID-19 (n=2219), therapeutic-dose anticoagulation with heparins increases survival to hospital discharge with reduced use of organ support. medrxiv.org/content/10.1101/…

Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19

Background Thrombo-inflammation may contribute to morbidity and mortality in Covid-19. We hypothesized that therapeutic-dose anticoagulation may improve outcomes in non-critically ill patients...

medrxiv.org
5
69
21
140
Just had our @ACTIV4a v1.1 protocol review - we hope to start randomizing to yes/no P2Y12i in hospitalized #COVID19 very soon!!@macky_neal @LucyKornblith @ATTACC_COVID @MaryCushmanMD @PatrickLawlerMD @statberry
1
2
1
35
In this free access @bmj_latest editorial we discuss - the changing views & practice of thromboprophylaxis in hospitalised patients with COVI-19 through the pandemic - the recent RCT interim evidence from @remap_cap @ATTACC_COVID & @ACTIV4a as to what is the best dose of LMWH
Claire McLintock@doctormclintock20 Feb 2021
Honoured to have co-written this @BMJ editorial dx.doi.org/10.1136/bmj.n487 @bhwords @PaulaErich MertDumantepe #thromboprophylaxs for #COVID19 important comment on current knowledge - all members of @thrombosisday steering group.
1
43
5
72
Replying to @ToddNeale @Erik_Klok_MD
Was nice discussing thrombosis and antithrombotic Rx in #covid19 from the mpRCT between @ACTIV4a @ATTACC_COVID @remap_cap
1
3
Replying to @ATTACC_CAP
A brief thread on interpreting organ support-free days as an endpoint for RCTs including @ATTACC_COVID @remap_cap @ACTIV4a Visit the simulator linked here to explore how the endpoint is influenced by its various components bit.ly/3oFZ57j
1
5
2
10
We are releasing the interim (final data coming and publication submission pending) data from our amazing mpRCT collaboration w/ @ATTACC_COVID @remap_cap to aid in clinician decision making on anticoagulants for #COVID19: nhlbi-connects.org/documents… @nih_nhlbi @macky_neal
1
15
2
37
Early results of a worldwide trial, coordinated in part by researchers at Pitt, found that full doses of heparin, a blood thinner, were not only safe but also reduced the need for vital organ support, such as ventilation for COVID-19 patients. More here: bit.ly/3oemMDy
14
2
31
Replying to @ACTIV4a @AaronKornblith @UCSFchipper @UCSF_BCHSI @UCSFHospitals @UCSFSurgery
I’d say that the real forces of nature are @ACTIV4a @remap_cap @ATTACC_COVID and their tireless, dedicated, brilliant, amazing leadership. Grateful for the opportunity to learn from and work alongside all of you. – at San Francisco, CA
1
7
Important announcement from ATTACC, ⁦⁦@ACTIV4a⁩ and ⁦@remap_cap⁩: Full-dose blood thinners decreased need for life support and improved outcomes in hospitalized COVID-19 patients news.umanitoba.ca/blood-thin…

UM Today

umtoday.ca
12
117
36
215
Load more